• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Porcine Vaccines Market

    ID: MRFR/Pharma/5969-HCR
    90 Pages
    Rahul Gotadki
    October 2025

    Porcine Vaccines Market Research Report Information by Type (Inactivated Vaccines, DNA Vaccines), Disease Indication (Diarrhea, Swine Influenza), End User - Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Porcine Vaccines Market Infographic
    Purchase Options

    Porcine Vaccines Market Summary

    As per MRFR analysis, the Porcine Vaccines Market Size was estimated at 1.92 USD Billion in 2024. The Porcine Vaccines industry is projected to grow from 2.021 USD Billion in 2025 to 3.378 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.27 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Porcine Vaccines Market is experiencing robust growth driven by technological advancements and increasing awareness of animal health.

    • North America remains the largest market for porcine vaccines, driven by a well-established livestock industry.
    • The Asia-Pacific region is emerging as the fastest-growing market, reflecting rising investments in animal health.
    • Inactivated vaccines dominate the market, while live attenuated vaccines are witnessing rapid growth due to their effectiveness.
    • Key drivers include the increasing incidence of porcine diseases and regulatory support for vaccine development.

    Market Size & Forecast

    2024 Market Size 1.92 (USD Billion)
    2035 Market Size 3.378 (USD Billion)
    CAGR (2025 - 2035) 5.27%

    Major Players

    Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Vetoquinol (FR), Huvepharma (BG), Phibro Animal Health (US), IDT Biologika (DE)

    Porcine Vaccines Market Trends

    The Porcine Vaccines Market is currently experiencing a dynamic evolution, driven by various factors that influence both production and consumption. The increasing global demand for pork, coupled with heightened awareness regarding animal health, has led to a surge in vaccine development aimed at preventing diseases in swine populations. This trend is further supported by advancements in biotechnology, which enable the creation of more effective and targeted vaccines. Additionally, regulatory frameworks are becoming more stringent, prompting manufacturers to innovate and comply with safety standards, thereby enhancing the overall quality of vaccines available in the market. Moreover, the Porcine Vaccines Market is witnessing a shift towards preventive healthcare measures, as stakeholders recognize the economic implications of disease outbreaks in livestock. This proactive approach not only safeguards animal welfare but also ensures food security for the growing global population. The integration of digital technologies in vaccine distribution and monitoring is also emerging, potentially streamlining processes and improving traceability. As the market continues to adapt to these changes, it appears poised for sustained growth, with opportunities for new entrants and established players alike to contribute to advancements in swine health management.

    Rising Demand for Sustainable Practices

    The Porcine Vaccines Market is increasingly influenced by the demand for sustainable farming practices. Producers are seeking vaccines that not only enhance animal health but also align with environmental stewardship. This trend suggests a shift towards more eco-friendly vaccine formulations and production methods.

    Technological Advancements in Vaccine Development

    Innovations in biotechnology are playing a crucial role in the Porcine Vaccines Market. The development of novel vaccine platforms, such as mRNA technology, appears to enhance efficacy and reduce production times. This trend indicates a potential for more rapid responses to emerging diseases.

    Focus on Preventive Health Strategies

    There is a growing emphasis on preventive health measures within the Porcine Vaccines Market. Stakeholders are increasingly recognizing the economic benefits of vaccination programs, which may lead to reduced disease incidence and improved herd productivity. This focus on prevention could reshape market dynamics.

    The ongoing advancements in vaccine technology and the increasing awareness of animal health are driving a notable shift towards more effective porcine vaccines, which may enhance biosecurity measures in the swine industry.

    U.S. Department of Agriculture (USDA)

    Porcine Vaccines Market Drivers

    Advancements in Vaccine Technology

    Advancements in vaccine technology are significantly influencing the Porcine Vaccines Market. Innovations such as recombinant vaccines and DNA vaccines are emerging as effective alternatives to traditional methods. These new technologies offer enhanced efficacy and safety profiles, which are crucial for gaining acceptance among producers. Moreover, the ability to develop vaccines that target multiple pathogens simultaneously could streamline vaccination processes and reduce costs. As research continues to evolve, the market is likely to see a surge in the availability of advanced vaccine options, catering to the diverse needs of the swine industry. This technological evolution is expected to play a pivotal role in shaping the future landscape of porcine vaccination.

    Economic Growth in Emerging Markets

    Economic growth in emerging markets is contributing to the expansion of the Porcine Vaccines Market. As these regions experience increased investment in agriculture and livestock production, the demand for effective vaccination solutions is on the rise. The growing middle class in these markets is also driving the demand for high-quality pork products, which necessitates improved animal health management practices. Consequently, producers are more inclined to invest in vaccines to ensure the health of their herds. This trend indicates a promising opportunity for vaccine manufacturers to penetrate these markets, as they seek to meet the rising demand for porcine vaccines that can enhance productivity and animal welfare.

    Increasing Incidence of Porcine Diseases

    The rising incidence of porcine diseases, such as Porcine Reproductive and Respiratory Syndrome (PRRS) and Swine Influenza, is a primary driver for the Porcine Vaccines Market. These diseases have led to significant economic losses in the swine industry, prompting farmers and producers to seek effective vaccination solutions. According to recent data, the economic impact of PRRS alone can reach billions annually, underscoring the urgency for vaccination. As awareness of these diseases grows, the demand for innovative vaccines that can provide effective protection is likely to increase. This trend indicates a robust market potential for vaccine manufacturers, as they strive to develop products that can mitigate the impact of these diseases on swine health and productivity.

    Regulatory Support for Vaccine Development

    Regulatory bodies are increasingly supporting the development and approval of vaccines for porcine diseases, which is a significant driver for the Porcine Vaccines Market. Initiatives aimed at streamlining the approval process for new vaccines can enhance market entry for innovative products. For instance, the introduction of expedited review processes for vaccines targeting high-impact diseases may encourage investment in research and development. This regulatory support not only fosters innovation but also ensures that effective vaccines reach the market more swiftly. As a result, the overall growth of the porcine vaccine sector is likely to be bolstered by favorable regulatory environments that prioritize animal health and welfare.

    Growing Awareness of Animal Health and Welfare

    There is a growing awareness of animal health and welfare among consumers and producers, which is driving the Porcine Vaccines Market. As consumers become more conscious of the conditions under which livestock are raised, there is an increasing demand for products that ensure the health and well-being of animals. This trend is reflected in the rising adoption of vaccination programs aimed at preventing diseases in pigs. Furthermore, producers are recognizing that healthy animals lead to better productivity and profitability. Consequently, the emphasis on animal welfare is likely to propel the demand for effective vaccines, as stakeholders seek to align with consumer expectations and regulatory standards.

    Market Segment Insights

    By Type: Inactivated Vaccines (Largest) vs. Live Attenuated Vaccines (Fastest-Growing)

    In the Porcine Vaccines Market, the type of vaccine significantly influences market share dynamics. Inactivated vaccines dominate the market due to their proven efficacy and safety profile, being a preferred choice among veterinarians and pig farmers. Meanwhile, live attenuated vaccines follow closely, leveraging their ability to provide rapid immunity and stimulate robust immune responses, making them popular for preventive measures against prevalent diseases in swine populations. The growth trends in this segment are propelled by increasing awareness of swine health and a rise in pig farming practices globally. Additionally, advances in vaccine technology, such as the development of recombinant and DNA vaccines, are creating new opportunities within the market. As such, prioritizing health management in livestock is becoming increasingly essential, further driving demand for innovative vaccine solutions.

    Inactivated Vaccines (Dominant) vs. Recombinant Vaccines (Emerging)

    Inactivated vaccines are a dominant force within the Porcine Vaccines Market, known for their reliability and safety. These vaccines are often preferred in commercial pig farming due to their ability to elicit strong immune responses without the risk of disease transmission. On the other hand, recombinant vaccines are emerging as a significant alternative, utilizing advanced biotechnology to enhance efficacy and safety. They provide specific protection against certain pathogens, showcasing quicker development cycles and the potential for stability in various storage conditions. As animal health protocols evolve, the introduction and acceptance of recombinant vaccines are likely to increase, catering to the industry’s demand for more effective immunization strategies against evolving diseases.

    By Disease Indication: PED (Largest) vs. PRRS (Fastest-Growing)

    In the Porcine Vaccines Market, the market share distribution is dominated by the Porcine Epidemic Diarrhea (PED) vaccine, which holds the largest share among disease indications. Following PED, the Porcine Reproductive & Respiratory Syndrome (PRRS) vaccine is also significant, emerging as the fastest-growing segment. Other notable competitors in the market include Swine Influenza, Aujeszky's Disease, and Porcine Circovirus Associated Disease (PCVAD), all of which contribute to the overall market landscape, but with lesser shares than the leading segments. The growth trends within this segment are largely driven by rising incidence rates of the diseases and heightened awareness of the economic impacts of these conditions on swine production. Additionally, advancements in vaccine technology and increased investments in research and development are further propelling market growth. The ongoing emphasis on biosecurity and disease prevention among swine producers underscores the critical need for effective vaccination programs, thereby bolstering the demand for these vaccines.

    PED (Dominant) vs. PRRS (Emerging)

    The Porcine Epidemic Diarrhea (PED) vaccine remains the dominant force in the Porcine Vaccines Market, known for its crucial role in controlling outbreaks of this highly contagious disease, which can significantly impact pig mortality rates and production efficiency. The high levels of awareness and preventive measures taken by producers have reinforced the strong market position of PED vaccines. Conversely, the Porcine Reproductive & Respiratory Syndrome (PRRS) vaccine is positioned as an emerging segment, experiencing rapid growth due to an increase in the prevalence of PRRS in swine herds. The continuous challenges posed by this respiratory disease are leading to heightened innovation and adoption of effective PRRS vaccines, as producers strive to mitigate the health impacts on their livestock.

    By End-user: Hog Production Farm (Largest) vs. Veterinary Hospitals (Fastest-Growing)

    In the Porcine Vaccines Market, the end-user segment is primarily dominated by hog production farms, which utilize a vast majority of the vaccines to ensure herd health and productivity. These farms require continuous vaccination for disease prevention, making them a key player in the market. Veterinary hospitals, while representing a smaller portion of the market share, are increasingly significant as they often play a vital role in the distribution and administration of porcine vaccines, catering to smaller livestock operations and niche markets.

    End-User: Hog Production Farm (Dominant) vs. Veterinary Hospitals (Emerging)

    Hog production farms are characterized by their large-scale operations and focus on maximizing health outcomes for their herds through preventive measures, including vaccination. The demand for vaccines in these settings is driven by the need for maintaining herd immunity and productivity. In contrast, veterinary hospitals are emerging as vital players in the market, particularly as awareness of animal health rises among smaller producers. These facilities offer not only vaccination services but also consultations, diagnostics, and treatment, catering to a specialized clientele. As the industry evolves, both segments are crucial to ensuring the overall health of pig populations.

    Get more detailed insights about Porcine Vaccines Market

    Key Companies in the Porcine Vaccines Market market include

    Industry Developments

    In the year 2021

    The vaccine was created together and manufactured using CrisBio. This improved the rate of vaccine sales in the market. 

    Intended Audience

      • Porcine vaccines manufacturers
      • Porcine vaccines suppliers
      • Private research laboratories
      • Research and development (R&D) companies
      • Market research and consulting service providers
      • Government research laboratories
      • Contract manufacturing organizations

    Future Outlook

    Porcine Vaccines Market Future Outlook

    The Global Porcine Vaccines Market is projected to grow at a 5.74% CAGR from 2024 to 2035, driven by rising demand for disease prevention and advancements in vaccine technology.

    New opportunities lie in:

    • Developing next-generation vaccines targeting emerging porcine diseases.
    • Expanding distribution networks in developing regions to enhance market access.
    • Investing in R&D for vaccine formulations that improve efficacy and reduce costs.

    By 2035, the market is expected to achieve robust growth, positioning itself as a leader in animal health.

    Market Segmentation

    Porcine Vaccines Type Outlook

    • Inactivated vaccines
    • Live attenuated vaccines
    • Toxoid vaccines
    • Recombinant vaccines
    • Conjugate vaccines
    • DNA vaccines

    Porcine Vaccines End-user Outlook

    • Veterinary Hospitals
    • Hog Production Farm

    Porcine Vaccines Regional  Outlook

    • Americas North America US Canada
    • North America US Canada
    • US
    • Canada
    • Latin America
    • Europe Western Europe Germany France Italy Spain UK Rest of Western Europe
    • Western Europe Germany France Italy Spain UK Rest of Western Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific Japan China India Australia South Korea Rest of Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • The Middle East & Africa Middle East Africa
    • Middle East
    • Africa

    Porcine Vaccines Disease Indication Outlook

    • PED (Porcine Epidemic Diarrhea)
    • PRRS (Porcine Reproductive & Respiratory Syndrome)
    • Swine influenza
    • Aujeszky's disease (AD)
    • Porcine Circovirus Associated Disease (PCVAD)
    • Others

    Report Scope

    Report Attribute/Metric Details
      Market Size 2023   USD 1.79 Billion
      Market Size 2024   USD 1.92 Billion
      Market Size 2032   USD 3.04 Billion
      CAGR   5.27%
      Base Year   2023
      Forecast Period   2024-2032
      Historical Data   2022
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Disease indication, and End user
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Bayer AG, Bimeda, Inc., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company, Merck & Co. Inc., Sanofi S.A., Vetoquinol S.A.,Zoetis, Inc., PBS Animal Health, Aptimmune
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers ·  Rising number of biotechnology companies ·  Research organizations engaged in research and development of porcine vaccines ·  Government initiatives for funding agriculture and animal husbandry sector ·  Rising demand for porcine meat and gelatine

     

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions